• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Verily Launches Joint Venture to Develop & Commercialize Ophthalmic Devices

Share:

February 12, 2020

Highlights on this story:
  • Alphabet company Verily and Santen Pharmaceutical launch joint venture focused on developing and commercializing ophthalmic devices and comprehensive tech-enabled solutions.
  • The joint venture will focus on tackling ophthalmic conditions, such as glaucoma and dry eye.

Santen Pharmaceutical Co., Ltd. and Verily, an Alphabet company, announced the establishment of a joint venture focused on applying microelectronics and scalable digital technologies to ophthalmology. The new joint venture is driven by a mission to improve eye health for people everywhere, starting by developing solutions to support modern ophthalmology practice globally.

Worldwide Impact of Eye Health Issues

One in thirty people worldwide have experienced an issue with eye health and it is estimated that about 80% of visual impairments can be prevented by early detection and treatment. 1 In the healthcare industry, digital tools and technologies may present a meaningful way to develop more preventive and proactive solutions.

Joint Venture Details

Combining Santen’s industry knowledge and technology in ophthalmology and Verily’s expertise in the development of connected, integrated medical devices and machine learning, the new company plans to create and commercialize unique ophthalmic devices and comprehensive tech-enabled solutions.

“We’re thrilled to partner with Santen, a global company with an established presence in the ophthalmology industry, to develop novel solutions leveraging microelectronics and machine learning for better eye care. Our focus is first and foremost on taking care of patients. By combining Santen’s expertise and Verily’s advanced technology, our joint venture is well-positioned to tackle innovative projects spanning ophthalmic conditions, such as glaucoma and dry eye. We’ll explore ways to use technology not only to diagnose disease, but to improve treatment and develop more precise interventions in ophthalmology,” said Dimitri Azar, MD, MBA, Senior Director of Ophthalmic Innovation at Verily and CEO-designate of the joint venture.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Source: Hit Consultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Viva Biotech and SYNthesis Enters a Strategic Acquisition Agreement, Accelerating the Development of Global Innovative Drug R & D Service CapabilitiesViva Biotech and SYNthesis Enters a Strategic Acquisition Agreement, Accelerating the Development of Global Innovative Drug R & D Service Capabilities
  • FundamentalVR Closes $5M Series AFundamentalVR Closes $5M Series A
  • DarioHealth, Williams Medical Partner to Expand Digital Therapeutics Platform Across the UK and IrelandDarioHealth, Williams Medical Partner to Expand Digital Therapeutics Platform Across the UK and Ireland
  • Satio Partners with BARDA DRIVe to Develop a Novel Patch-Based Ebolavirus DiagnosticSatio Partners with BARDA DRIVe to Develop a Novel Patch-Based Ebolavirus Diagnostic
  • Mergers, acquisitions playing role in achieving scale, marketplace competitionMergers, acquisitions playing role in achieving scale, marketplace competition
  • Healthcare Specific MSP Medicus IT Acquires Phoenix Based ISDesignHealthcare Specific MSP Medicus IT Acquires Phoenix Based ISDesign
  • Eli Lilly and Company in Collaboration with Strateos, Inc. Launch Remote-Controlled Robotic Cloud LabEli Lilly and Company in Collaboration with Strateos, Inc. Launch Remote-Controlled Robotic Cloud Lab
  • Analysis: Applying AI in the Fight Against The CoronavirusAnalysis: Applying AI in the Fight Against The Coronavirus

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications